
HIV prevention research - a new forum for advocacy on the latest

# Привіт нашим друзям з України.

Hello to our friends from Ukraine.

#### **Webinar Logistics**



- Ukrainian translation is being offered today. Please click on "Interpretation" and choose English or Ukrainian.
- This call will be recorded. Your presence = consent.
- Please stay on mute, unless you are speaking.
- Please comment, ask questions, share info/resources in the chat.
- Let's hear your voice and see your face too. Raise hand to speak on camera.



 We will share links to recording and slides in follow-up email.
 They will be posted here: avac.org/choice-agenda



Next Wednesday TCA Presents





#### **HIV Prevention Plus Plus:**

Developing Options that Meet the Full Range of our Sexual and Reproductive Health Needs

More info, register:

tinyurl.com/hivpreventionplusplus



#### BROUGHT TO YOU BY







# BEEN THERE DID THAT

#### RESEARCH REFLECTIONS FROM #CR012023

Register at Zoom

🗰 23rd March, 2023

O9:00 - 10:30 CST 15:00 - 16:30 CET





RESEARCH REFLECTIONS FROM #CROI2023

#### MARCH 23 2023

09:00 - 10:30 CST/ 15:00 - 16:30 CET

Speakers will include community leaders and researchers reflecting on the most interesting, consequential science presented at CROI 2023.

CO-MODERATED BY DEVAN NAMBIAR, GAY MEN'S SEXUAL HEALTH ALLIANCE AND CROI 2023 COMMUNITY EDUCATOR SCHOLAR

FEATURED RESEARCHER: DR. MONICA GANDHI, UCSF

FEATURED COMMUNITY SPEAKERS: CROI 2023 COMMUNITY EDUCATOR SCHOLARS

Live interpretation in 🗫 will be provided.












#### CROI 2023 Community Educator Scholars



- Botswana
- Canada
- eSwatini
- Italy
- Kenya
- Latvia
- Nigeria
- South Africa
- Tanzania
- Uganda
- United States
- Zambia



## Quick Margarita Metrics

- 3 webinars
- 3 moderators
- 7 invited speakers
- 573 total registrations
- 326 unique individuals
- 349 individuals joined live
- 8 support staff (AVAC, EATG)
- 1 persistent porn-bomber
- 1 DJ

How do I access the Margarita Breakfast Club?

It's one of my favorite things.

- Betsy McKay, Wall Street Journal







# **CROI 2023 Community**



CROI 2023
Opening Plenary
Martin Delaney
Presentation

Yvette Raphael Executive Director

Advocacy for Prevention of HIV and AIDS

Recording croiconference.org/preliminary-agenda

**Yvette starts 1:12** 






All webcasts and other CROI materials are now available to all - as of 22 March. Enjoy.





# Now let's get started







# ROUND 1 SCHOLAR REFLECTIONS

### Research Reflections from CROI 2023 Devan Nambiar, Canada

- Plenary. Dr. Janet Siliciano. HIV Reservoirs: Obstacles to a Cure
- Plenary. Dr. George A. Kuchel. The Science of Aging. Lessons for HIV
- Ramgopal et al. SOLAR 12-Month Results: Randomized Switch trial of CAB+RPV La vs. Oral B/FTC/TAF
- Pinto-Cardoso et al. Changes in Gut Microbiota Profile in PLHIV Who Switch from EFV/FTC/TDF to BIV/FTC/TAF
- Poster (00376). Humoral and Cellular Immune Response After 3
   Months from MPOX virus Infection
- Poster (466): Cocaine use independently predicts white matter lesion burden in HIV disease







CROI 2023 provided a unique opportunity for me to network with the highest levels of leadership in the HIV space, learn from their experiences, and form new connections.



















Adaobi Lisa Olisa, Nigeria – CROI 2023 Community Scholar

#### My Top Research Highlights from the Conference are:


- 1) As a Youth Advocate, I was excited to learn that adolescents and young people, especially in Africa, are one of the priorities for PEPFAR's future research because we are disproportionately affected by HIV.
- 2) I was enlightened on the importance of including pregnant and breastfeeding populations (PBFP) in research studies. Their exclusion from research has led to the limited or complete absence of safety information for them, which often delays or limits their access to new products/interventions.
- 3) The session on "The Power of Community Engagement for Advancing Research" inspired me and resonated with my work with the **MOSAIC** NextGen Squad as we support implementation research for the new PrEP products across 5 African countries.

I am excited to share the insights from CROI 2023 with the MOSAIC NGS and apply them to our work as we continue to support the expansion of the HIV prevention landscape

#### Mercy Mutonyi, Kenya

CROI Community Educator Scholar AVAC fellow 2019

- As a young woman having attended CROI at 30 there's so much to be hopeful in the current and future HIV prevention research and programming.
- I see a future where HIV prevention and treatment is not perceived as cumbersome, expensive and with limited options. For instance, it was very comforting to learn that dapivirine vaginal ring (DVR) has been found to be safe for pregnant and lactating people and their babies. Often, communities are left out when it comes to HIV prevention research and designing prevention tools.
- CROI at 30 strongly reinforced the role of the community in HIV science through participation of Community Scholars. Voices of young people, women living with HIV, female sex workers and other vulnerable population count when it comes to designing HIV prevention and treatment approaches.



#### TALKMORE TAURAI MAZORODZE

#### **CROI 2023 COMMUNITY SCHOLAR**

TRUNCATE-TB TRIAL

**ESWATINI** 

(Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive TB)



- > TRUNCATE-TB trial evaluated an alternative strategy to treat DS-TB for 2 months (8wks that could extented to 12wks) compared to the standard treatment strategy of using multiple drugs for 6months.
- A randomized, open-label, multi-arm, multi-stage trial to test the hypothesis that the **TRUNCATE-TB** Strategy is non-inferior to the standard treatment strategy in terms of longer-term outcomes.
- The trial enrolled 675 participants across 18 sites in high TB-burden countries, including India, Uganda, Thailand, Phillipines and Indonesia.
- Participants were randomized into several treatment arms, with the standard arm receiving rifampin and isoniazid for 24 weeks (6mnths) and pyrazinamide and ethambutol for the first eight weeks.

#### **RESULTS**

- The arm that received an eight-week regimen of bedaquiline and linezolid, along with isoniazid, pyrazinamide and ethambutol, showed as much safety and efficacy as the standard six-month rifampin-based regimen.
- The 8-wk regimen for treating TB is just as efficacious and safe as the standard six-month regimen, which has been the standard of care for decades to treat TB.


#### WHAT DOES THIS MEAN (BENEFITS)

- Improved treatment adherence and treatment outcomes (shorter treatment period)
- Reduced drug resistence
- Resources could be redirected towards finding and treating more TB patients



## Catherine Madebe Tanzania





#### Been There, Did That - Research Reflections from CROI 2023

"HIV Cure is Rare: Elimination and Durable ART-Free Suppression"

"Research priorities: Youth/AYP, Children and people-centred care"

Yusuf Hassan Wada Nigeria



















**Plenary Session** 

Dr. John Nkegasong

# MY RESEARCH HIGHLIGHT FROM CROI 23

My biggest highlight was the study on the effectiveness of the long-acting injectable for HIV prevention and treatment in specific populations.

Long-acting HIV treatment can be used to reach people with multiple challenges to treatment adherence.

The safety and effectiveness of long-acting injectable cabotegravir (CAB-LA) for PrEP among Black MSM and transgender women who have sex with men was demonstrated, making it a very powerful HIV prevention tool to reduce incidence among the underserved population

The intervention was found to be safe, tolerable and acceptable to adolescent girls and young women.



Lusaka Zambia



#### Elri Voigt Community Educator Scholar South Africa


I had the privilege of attending CROI 2023 in person because of receiving the community educator scholarship. While it is difficult to pick just one, my top research highlight was results presented by Dr Adrienne Shapiro on a study conducted in South Africa which found that the use of Tuberculosis Preventive Therapy (TPT) increased when it was combined with community delivered Anti-retroviral therapy (ART).

It is encouraging to see research that is looking at ways to improve the uptake of TPT and that uses methods that could be implemented in real world clinic and community settings.

• The abstract was titled "Increased TB preventative therapy coverage with integrated community based IPT and ART."



#### DAVID EKPENYONG ITA, Nigeria



I enjoyed Dawn Averitt's session which talked about the imperative for inclusivity as regards community involvement in all aspects of research.

The session reminded me of what one of my mentors told us during a session with advocates in Nigeria that advocates should not see or allow themselves to be used as data collectors only, rather they should take charge and see themselves as partners by gaining ownership of research in all stages.

I left the conference optimistic about HIV cure in the future after listening to the presenters about the list of the most recent findings from clinical trials and the implications of these data for state-of-the-art treatment strategies.


The idea of also getting all stakeholders involved in all ramifications of research and working as a team is a clear sign that there is hope for HIV's future cure.

# END OF ROUND 1 SCHOLAR REFLECTIONS



Dr. Monica Gandhi presents

# ROUND 2 SCHOLAR REFLECTIONS



Community Educator Scholar Shakirah Namwanje, Uganda

# Bridgette Picou, United States Stakeholder Liaison The Well Project- HIV United States

#### My takeaways from CROI 2023

- 1. Breastfeeding guideline updates.
- 2. Doxycycline PEP after sex appears ineffective for cisgender women.
- 3. (MBC) The Data Gap:
  Filling in the Missing Perspectives
  on Women and Children in HIV
  Research



Thank you to the CROI Community
Liaison Subcommittee for working to ensure we as community members have a voice!

# CROI 2023 Community Educator Scholar

**Experience Sharing** 

"Attending the CROI Conference 2023 was an enlightening experience that provided me with valuable insights into the latest developments in HIV/AIDS research and treatment. Aside from the many research findings presented, I learned better strategies for communicating science in the age of misinformation; as a community without a proper understanding of HIV and other health-related services, they tend not to use them, delaying the attainment of set country and global health goals.

Furthermore, the conference emphasized the importance of continuing to invest in HIV research as well as tailoring HIV prevention and treatment programs to meet the specific needs of different populations. As a community advocate, I am committed to using these insights to advocate for better HIV and STI prevention and treatment programs in Tanzania that meet the needs of the community."

- Francis Luwole, Community Advocate, Tanzania



## Highlights from CROI 2023

Jeff Berry, Community Educator Scholar The Reunion Project, USA



- lenacapavir + 2 bNAbs every 6 months
- Long-acting cabotegravir + rilpivirine for people not virally suppressed
- Fifth case of HIV cure declared during CROI 2023, the "Dusseldorf patient"
- HIV and aging plenary







# Community Educator Scholar Kennedy Eyoho, Botswana

#### Sandris Klavins, Latvia CROI 2023 Community Educator Scholar

#### **ALCOHOL USE – Research in this field is very scarce**

2016 XXI WAC (Durban)

Poster THPEB083

First controlled alcohol administration experiment to assess whether the level of objective intoxication differs by HIV serostatus. Researchers discovered that blood alcohol concentration (BAC) had been significantly lower among HIV+ participants. Viral load and taking ART were not significantly associated with BAC.

#### 2023 XXX CROI (Seattle)

Poster #883

Unhealthy alcohol use is a major contributor to viral non-suppression (VL>400) among PWH.






#### Sandro Matellioli Italy

The reason for my presence at CROI is to bring back to my country scientific studies, the state of the art on HIV, the innovations that I believe may be useful for Italy and for LGBT people living with HIV in Italy. I tried to understand the state of the art on vaccines, on cure, on treatment, mpox, PEPFAR, on reservoirs and why they block the possibility of realizing a cure for HIV. I always have in mind the empowerment of people with HIV so that they can be responsible for their own health and not blindly depend on others. That's why I go to science conferences. We, here in Italy, have to fight against stigma, prejudice and a creeping provincialism that makes it difficult even for doctors to promote U=U. CROI is a unique opportunity to draw on first-hand information, without going through the opinion of Italian infectious disease specialists. This is very important to us because it helps us in the work of empowering people with HIV and stimulates us to fight against the backward mentality of many Italian researchers..



- Introduction to CROI 2023 (https://www.plusaps.it/2023/02/20/croi-2023introduzione/)
- HIV: THE STATE OF THE ART treatment naive, resistance and experienced (https://www.plusaps.it/2023/02/20/croi-2023-hiv-lostato-dellarte/)
- PEPFAR, Doxy PEP, Doxyvac, and STI (https://www.plusaps.it/2023/02/21/croi-2023-pepfardoxy-y-otras-chicas-del-monton/)
- Results form Mosaico vaccine study (https://www.plus-aps.it/2023/02/22/croi-2023-mosaico/)
- HIV reservoirs, COVID-19, and Mpox (https://www.plus-aps.it/2023/02/22/croi-2023-reservoir-e-mpox/)
- HIV and aging (https://www.plusaps.it/2023/02/22/croi-2023-aging/)
- Poster: Mpox: Sexual behavior reduction do not explain decreased Mpox incidence among PrEP users (https://www.plus-aps.it/2023/02/25/croi-2023-poster/)





Dr. Monica Gandhi presents